Strategic partnerships AC Immune has a history of securing strategic partnerships with leading global pharmaceutical companies, generating substantial non-dilutive funding and potential milestone payments. This indicates a strong openness to collaboration, licensing, and co-development opportunities that BD teams can leverage to propose partnerships around their SupraAntigen and Morphomer platforms or specific programs.

Neurodegenerative focus The company specializes in precision prevention for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, with a broad and diversified pipeline including diagnostics and therapeutics at multiple development stages. This presents sales opportunities for CROs, contract research, imaging agents, and diagnostic tool providers targeting neurology-focused pharma partners or clinical trial sponsors.

Clinical-stage momentum With several programs in Phase 2 and one in Phase 3, AC Immune maintains clinical-stage momentum and active data generation, including in vivo PET imaging tracers. BD teams can target pharmaceutical sponsors seeking collaboration on late-stage assets, imaging biomarkers, or co-development deals that align with their 2026 conference activities.

Recent leadership changes The recent retirement of CEO Andrea Pfeifer may signal strategic realignment or new partnership directions. This could be an opportunity to engage leadership with fresh perspectives on collaboration, licensing, or funding structures that support ongoing innovation and pipeline advancement.

Funding and scale fit AC Immune maintains moderate revenue and established funding sources, plus a track record of non-dilutive support from partnerships, suggesting a company open to deal structures that minimize equity dilution. This is favorable for proposing milestone-based licenses, co-development deals, or milestone-rich collaborations with global pharma players seeking neurodegenerative program access.